JHVEPhoto/iStock Editorial via Getty Images
The Federal Trade Commission announced on Wednesday that Teva Pharmaceutical (TEVA), under pressure from the agency, has requested the removal of more than 200 patents improperly listed in the FDA’s official register of drugs, known as the “Orange Book.”
The